Document Detail

Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer.
MedLine Citation:
PMID:  18035537     Owner:  NLM     Status:  MEDLINE    
We have previously shown that TS/A murine mammary adenocarcinoma cells, induced to express high surface expression of MHC class II molecules by stable transfection of CIITA, resulted in high rate (92%) of tumor rejection and tumor immunity to subsequent homologous tumor challenges. The immunological basis of tumor response is based on tumor-specific CD4(+) T helper type 1 (Th1) in the priming phase and tumor-specific CD8(+) T cells as the major effector cells. IL-12 is the crucial cytokine that drives Th1 polarization in conjunction with inducing strong cellular-based immune responses. We have previously shown in the same tumor model that a naked DNA IL-12 gene transfer was effective in preventing tumor angiogenesis in an immunopreventive approach when administrated at least 2 days prior to the tumor inoculation. Here we indicate that the combination of the two approaches in immunotherapy of established tumors is efficacious in delaying tumor growth but not in completely eradicating the tumor.
Lorenzo Mortara; Luca Giuliani; Andrea De Lerma Barbaro; Roberto S Accolla; Douglas M Noonan
Related Documents :
18566377 - In vitro and in vivo down-regulation of regulatory t cell activity with a peptide inhib...
11267967 - Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lympho...
8324737 - Two competing influences that may explain concomitant tumor resistance.
15805297 - Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection o...
18161657 - Matrix metalloproteinase-19 is a predictive marker for tumor invasiveness in patients w...
15183487 - Effect of rsr13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2007-11-26
Journal Detail:
Title:  Surgical oncology     Volume:  16 Suppl 1     ISSN:  0960-7404     ISO Abbreviation:  Surg Oncol     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-10     Completed Date:  2008-04-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208188     Medline TA:  Surg Oncol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  S33-6     Citation Subset:  IM    
Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Via Ottorino Rossi, 9-21100 Varese, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / immunology*
Gene Therapy
Genes, MHC Class II
Immunotherapy, Adoptive
Interleukin-12 / genetics,  metabolism
Mammary Neoplasms, Animal / immunology*
Nuclear Proteins / biosynthesis,  immunology*
Trans-Activators / biosynthesis,  immunology*
Reg. No./Substance:
0/MHC class II transactivator protein; 0/Nuclear Proteins; 0/Trans-Activators; 187348-17-0/Interleukin-12

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Laparoscopic rectal resection with intraoperative radiotherapy in locally advanced cancer: prelimina...
Next Document:  Colorectal cancer: the role of laparoscopy.